The Diagnosis and Treatment Process for Acromegaly: What to Know

Acromegaly arises from excess growth hormone, often due to a pituitary adenoma. Understanding how it is identified and managed can clarify common steps: hallmark symptoms and biochemical testing, imaging to locate the source, and treatment pathways such as surgery, medications, and radiation. Key goals include controlling hormone levels, reducing tumor effects, and monitoring long‑term health.

Understanding Acromegaly and Its Causes

Acromegaly is a hormonal condition driven by chronically elevated growth hormone (GH) and insulin-like growth factor 1 (IGF‑1) after growth plates have fused. The most common source is a benign pituitary adenoma that secretes excess GH. Less commonly, elevated GH results from excess growth hormone–releasing hormone (GHRH) produced by neuroendocrine tumors outside the pituitary, which secondarily stimulates the pituitary to release GH. Rare genetic contexts—such as multiple endocrine neoplasia type 1 (MEN1), aryl hydrocarbon receptor-interacting protein (AIP) mutations, and McCune‑Albright syndrome—can increase risk for pituitary adenomas presenting with acromegaly.

Recognizing Signs and Symptoms

Gradual onset and subtle progression often delay recognition. Common features include:

  • Enlargement of hands and feet; rings and shoes no longer fit over time
  • Coarsening of facial features, jaw protrusion (prognathism), and tooth spacing
  • Skin thickening, excessive sweating, and skin tags
  • Joint pain, carpal tunnel syndrome, and reduced range of motion
  • Headaches and visual field changes (often bitemporal hemianopsia) due to tumor compression
  • Metabolic changes such as elevated blood glucose, dyslipidemia, and weight changes
  • Cardiovascular manifestations including hypertension and cardiomyopathy
  • Respiratory issues such as obstructive sleep apnea In adolescents with open growth plates, excess GH leads to excessive linear growth (gigantism) rather than acromegalic changes alone.

Step-by-Step Diagnostic Pathway

Diagnosis integrates clinical suspicion with biochemical confirmation and imaging.

  1. Initial screening with IGF‑1:
  • IGF‑1 reflects average GH exposure and is typically elevated above age- and sex-adjusted reference ranges in active acromegaly.
  • Normal or borderline IGF‑1 with strong clinical cues may require repeat testing or evaluation for factors that affect IGF‑1 (malnutrition, liver disease, uncontrolled diabetes, pregnancy, and certain medications).
  1. GH suppression testing:
  • The oral glucose tolerance test (OGTT) assesses GH suppression; in healthy physiology, glucose suppresses GH to very low levels. Failure to suppress supports the diagnosis.
  • Pre-test conditions and assay variability can influence interpretation; results are considered alongside IGF‑1 and clinical context.
  1. Pituitary imaging:
  • High-resolution pituitary MRI with contrast is the standard to detect microadenomas (<10 mm) or macroadenomas (≥10 mm), assess invasion of surrounding structures (cavernous sinus, suprasellar region), and guide treatment planning.
  • If MRI is negative but biochemical evidence is strong, repeat imaging or dynamic sequences may be considered. Evaluation for ectopic GHRH/GH sources can be pursued in select scenarios.

Differential Diagnosis and Confounders

Several conditions can mimic features of acromegaly or alter laboratory values:

  • Pseudoacromegaly syndromes with insulin resistance can cause soft tissue overgrowth without elevated GH/IGF‑1.
  • Chronic kidney or liver disease and poorly controlled diabetes can raise GH or alter IGF‑1 binding proteins.
  • Pregnancy, adolescence, and severe malnutrition affect GH/IGF‑1 physiology.
  • Medications such as estrogens (oral forms) can alter IGF‑1 and GH dynamics.

Baseline Health Assessment at Diagnosis

A comprehensive baseline helps define severity and guide management:

  • Metabolic profile: fasting glucose or HbA1c, lipid panel
  • Cardiovascular evaluation: blood pressure, echocardiogram if cardiomyopathy suspected
  • Respiratory assessment: screening for obstructive sleep apnea, often with sleep studies
  • Colon health: consideration of colonoscopy due to an association with increased colonic polyps
  • Bone and joint status: evaluation for arthropathy and vertebral changes
  • Pituitary function: assessment for hypopituitarism (thyroid, adrenal, gonadal axes), particularly with macroadenomas

Treatment Goals and Response Criteria

Treatment generally aims to:

  • Normalize IGF‑1 for age and sex
  • Suppress GH to levels consistent with biochemical control
  • Reduce tumor size and relieve mass effect on optic pathways and surrounding structures
  • Improve symptoms and reduce risks associated with long-term GH/IGF‑1 excess Biochemical control is typically defined by normal IGF‑1 and adequate GH suppression on dynamic testing, interpreted with consistent assays and clinical findings.

Surgical Management

Transsphenoidal surgery is commonly pursued for pituitary adenomas when feasible. Key considerations:

  • Indications include symptomatic macroadenomas, optic compression, and tumors accessible via the sphenoid sinus corridor.
  • Remission rates vary by tumor size, invasion, and surgical technique. Microadenomas without invasion have higher rates of biochemical control.
  • Potential risks include cerebrospinal fluid leak, new hypopituitarism, diabetes insipidus, and, rarely, vascular or visual complications.
  • Postoperative evaluation includes early IGF‑1 and GH measurements and follow-up MRI to assess residual tumor.

Medical Therapy Options

Pharmacologic therapy is used as primary treatment when surgery is not suitable, as adjunct therapy for incomplete surgical control, or while awaiting radiotherapy effects.

  • Somatostatin receptor ligands (SRLs): Octreotide and lanreotide reduce GH secretion and can shrink tumors in many cases. Long-acting formulations allow dosing at extended intervals. Common effects include gastrointestinal discomfort, gallstones, and changes in glucose regulation. Pasireotide targets broader receptor subtypes and may offer additional tumor and hormone control with a higher likelihood of hyperglycemia.
  • GH receptor antagonist: Pegvisomant blocks GH action at the receptor, lowering IGF‑1 regardless of tumor secretory activity. It does not shrink the tumor, so MRI surveillance continues. Liver function monitoring is standard with this therapy.
  • Dopamine agonists: Cabergoline can lower GH/IGF‑1 in some individuals, especially with modest elevations. It is often considered as add-on therapy. Potential effects include nausea, orthostatic symptoms, and, with long-term high doses, rare valvular changes.

Combination regimens (for example, SRL plus pegvisomant, or SRL plus cabergoline) can be tailored to biochemical response and tolerability.

Radiation Therapy Approaches

Radiation is considered for persistent or recurrent disease when surgery and medications do not achieve control or are not suitable.

  • Stereotactic radiosurgery (SRS): Delivers a focused high dose in a single or few sessions, best for well-defined residual tumors away from critical structures. Hormonal normalization may take months to years.
  • Fractionated radiotherapy (FRT): Administers smaller doses over many sessions, useful for larger or irregularly shaped tumors close to sensitive tissues.
  • Long-term considerations: Hypopituitarism is the most frequent delayed effect; periodic hormonal testing is essential. Radiographic changes and rare cranial nerve effects can occur, so imaging surveillance continues.

Monitoring After Treatment

Long-term follow-up supports sustained control and early detection of recurrence:

  • Biochemical testing: IGF‑1 at regular intervals; GH suppression testing as needed for confirmation or if results are discordant.
  • Imaging: MRI to monitor residual tumor or recurrence; frequency depends on initial tumor size, treatment modality, and stability over time.
  • Pituitary function: Periodic assessment for evolving hypopituitarism, especially after radiation or in the presence of a macroadenoma.
  • Comorbidity management: Ongoing attention to sleep apnea, glucose metabolism, blood pressure, cardiac structure and function, joint health, and colon screening schedules.
  • Quality-of-life tracking: Structured questionnaires can help characterize symptom burden and treatment impact.

Special Situations

  • Adolescents and gigantism: Excess GH before epiphyseal fusion leads to accelerated linear growth. Diagnostic principles are similar, with attention to growth velocity and bone age assessment. Treatment emphasizes prompt control to mitigate height progression and metabolic effects.
  • Pregnancy: Physiological changes affect GH/IGF‑1 measurement and interpretation. Many medications are adjusted or paused during pregnancy; management focuses on symptom monitoring and visual fields, with imaging reserved for concerning changes.
  • Ectopic GHRH/GH production: When pituitary imaging is negative or shows diffuse pituitary enlargement without a discrete adenoma, evaluation for neuroendocrine tumors (such as in the lungs or pancreas) may be considered. Measuring plasma GHRH and using cross-sectional imaging can aid localization.
  • Genetic predisposition: Family history of pituitary tumors or early-onset acromegaly may prompt genetic counseling and testing. Identifying a hereditary syndrome can guide surveillance for other endocrine tumors.

Practical Considerations in Care Planning

  • Sequencing of therapies depends on tumor size and location, biochemical severity, surgical accessibility, and individual health status.
  • Assay variability and laboratory reference ranges can influence interpretation; consistent testing methods over time aid trend analysis.
  • Lifestyle factors, including sleep, nutrition patterns, and joint protection strategies, are often discussed as part of comprehensive management, alongside medical treatments.
  • Long-term outlook depends on achieving and maintaining hormonal control and addressing associated conditions. Many systemic risks decrease as IGF‑1 normalizes, though joint and bony changes may persist, underscoring the value of early recognition and sustained follow-up.